Recent studies also reveal antimitotic therapies activating the cGAS/STING pathway directly in breast cancer cells (Zierhut et al., 2019), supporting better response to genotoxic treatments and immunotherapy (Schadt et al., 2019). Here, STING1 is linked to breast carcinoma.